Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clavulanic Acid in Remitted Cocaine Use Disorder
NCT03986762Phase 1Completed
- Sponsor
- Temple University
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of clavulanic acid in cocaine use disorder (CUD), sponsored by Temple University. Primary endpoints: Glutamate change from baseline and Glutamate/creatine ratio change from baseline. Started Mar 2019; status: completed.
02
Drugs
clavulanic acid
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT03986762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03986762.